Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial

The canary pox vector and gp120 vaccine (ALVAC-HIV and AIDSVAX B/E gp120) in the RV144 HIV-1 vaccine trial conferred an estimated 31% vaccine efficacy. Although the vaccine Env AE.A244 gp120 is antigenic for the unmutated common ancestor of V1V2 broadly neutralizing antibody (bnAbs), no plasma bnAb...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS Pathog
Autori principali: Easterhoff, David, Moody, M. Anthony, Fera, Daniela, Cheng, Hao, Ackerman, Margaret, Wiehe, Kevin, Saunders, Kevin O., Pollara, Justin, Vandergrift, Nathan, Parks, Rob, Kim, Jerome, Michael, Nelson L., O’Connell, Robert J., Excler, Jean-Louis, Robb, Merlin L., Vasan, Sandhya, Rerks-Ngarm, Supachai, Kaewkungwal, Jaranit, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Sinangil, Faruk, Tartaglia, James, Phogat, Sanjay, Kepler, Thomas B., Alam, S. Munir, Liao, Hua-Xin, Ferrari, Guido, Seaman, Michael S., Montefiori, David C., Tomaras, Georgia D., Harrison, Stephen C., Haynes, Barton F.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2017
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342261/
https://ncbi.nlm.nih.gov/pubmed/28235027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.ppat.1006182
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi